Overview

Edgewise Therapeutics develops therapies for rare muscle disorders using a proprietary drug discovery platform. Its lead molecule, sevasemten (EDG 5506), targets the muscle motor protein myosin to reduce stress in fast skeletal muscle fibers, aiming to improve muscle health without affecting other muscle types. The company owns global development and commercialization rights to its programs and pursues strategic collaborations and asset acquisitions to accelerate its pipeline. Its focus is precision medicine for conditions like Duchenne muscular dystrophy, Becker muscular dystrophy, Limb Girdle muscular dystrophies, and McArdle disease. Overall, Edgewise seeks to deliver targeted treatments that protect and improve muscle health for patients and families affected by these rare diseases.